Log in

Relevant bibliographies by topics / Hypoglycaemic agents / Journal articles

To see the other types of publications on this topic, follow the link: Hypoglycaemic agents.

Journal articles on the topic 'Hypoglycaemic agents'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hypoglycaemic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mohajan, Devajit, and Haradhan Kumar Mohajan. "Oral Hypoglycaemic Agents: Non-Insulin Medications for Type 2 Diabetes Patients." Innovation in Science and Technology 3, no. 1 (2024): 23–31. http://dx.doi.org/10.56397/ist.2024.01.04.

Full text

Abstract:

Among type 2 diabetes (T2D) patients, oral medications are called oral hypoglycaemic agents (OHAs), which are preferred over injections due to convenience and acceptability. These are a group of drugs that have been used successfully worldwide for controlling T2D patients to reduce the high blood sugar. These can be classified as either hypoglycaemic agents, such as sulfonylureas and benzoic acid derivatives or antihyperglycaemic agents, such as Biguanides, α-glucosidase inhibitors, and Thiazolidinediones. Most of these stimulate β-cells of the Islets of Langerhans within the pancreas to produ

APA, Harvard, Vancouver, ISO, and other styles

2

Kermode, Allan G., Karen M. McNally, and David A. Joyce. "Sulphonylurea hypoglycaemic agents." Medical Journal of Australia 157, no. 10 (1992): 717–20. http://dx.doi.org/10.5694/j.1326-5377.1992.tb137447p.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Marshall, SM. "Oral hypoglycaemic agents." Practical Diabetes International 20, no. 7 (2003): S1—S4. http://dx.doi.org/10.1002/pdi.524.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

*, Dr. N. Tendu Pranadeep Dr. G. Gayathri Dr. B.Kavya Chowdary Dr.M.Anuhya Dr.C. Pradeep Dr. G. V. Nagaraju Dr.Md.K.Rahman Dr. Alias Kenny. "SAFETY AND EFFICACY OF TENELIGLIPTIN OVER OTHER HYPOGLYCEMIC AGENTS IN TYPE-2 DIABETES." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 07 (2018): 6325–40. https://doi.org/10.5281/zenodo.1310608.

Full text

Abstract:

To compare the safety and efficacy of the Teneligliptin a DPP inhibitor over other hypoglycaemic agents in Type II Diabetes Mellitus. .It is a prospective –observational study in this study was conducted at, Pradeep Diabetic Centre, Rajamahendravaram and the study was carried out for a period of 6 months from Feb 2016 to July 2016, and we are taking total of 114 patients with type 2 diabetes, in our study concludes the combination of Teneligliptin with other oral hypoglycaemic agents have been shown to improve glycaemic control efficiently when compare with the monotherapy shown inadequa

APA, Harvard, Vancouver, ISO, and other styles

5

MacMahon, Clare, Millie O'Gorman, John Martin, et al. "249 Is Our Diabetic Control Too Tight? An Audit of Management of Type II Diabetes in a Long Term Care Setting." Age and Ageing 48, Supplement_3 (2019): iii17—iii65. http://dx.doi.org/10.1093/ageing/afz103.153.

Full text

Abstract:

Abstract Background Recent guidelines on diabetes management recommend individualisation of management particularly in those with frailty or significant co-morbidities. The aim of our audit was to assess diabetic control of residents in a long term care setting. Studies have shown that intensive control in an older population increases the risk of hypoglycaemia and does not necessarily improve clinical outcomes. There is also evidence that increased pill burden and hypoglycaemic events negatively affect quality of life among older people. Methods 176 nursing home residents were assessed. Detai

APA, Harvard, Vancouver, ISO, and other styles

6

Dr., Syed Farasat Ali Shah Dr. Eesha Noor Dr. Ifaza Tariq. "TO DETERMINE THE FREQUENCY OF HYPOGLYCAEMIA IN DIABETIC PATIENTS TAKING ORAL HYPOGLYCAEMIC DRUGS/ INSULIN." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 11 (2018): 12376–81. https://doi.org/10.5281/zenodo.1490073.

Full text

Abstract:

<strong><em>Background: </em></strong><em>The risk of severe hypoglycemia is greatly increased in subjects having old age, renal failure, hepatic failure and pregnancy. The overall prevalence is 2–3%, and the lifetime risk is around 15%. </em> <strong><em>Objective: </em></strong><em>To determine the frequency of hypoglycemia in diabetic subjects taking oral hypoglycemic agents/ Insulin therapy.</em> <strong><em>Method: </em></strong><em>This cross-sectional study includes 250 out/in patient type 2 diabetic subjects visiting to Pakistan Institute of Medical Sciences that is a tertiary ca

APA, Harvard, Vancouver, ISO, and other styles

7

Ntouva, Antiopi, Konstantinos A. Toulis, Deepikshana Keerthy, et al. "Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: a cohort study." European Journal of Endocrinology 180, no. 1 (2019): 51–58. http://dx.doi.org/10.1530/eje-18-0458.

Full text

Abstract:

Objective Type 2 diabetes is associated with an increased risk of fracture. Any factor that incrementally increases this risk should be taken into account when individualising treatment. Hypoglycaemia is a common complication of antidiabetes medications and suggested as a risk factor for fractures; yet, its real-life clinical impact is unclear. Design A population-based, retrospective open cohort study using routinely collected data between 1st of January 1995 and 1st of May 2016 in The Health Improvement Network (THIN) database. Methods Patients with type 2 diabetes mellitus with documented h

APA, Harvard, Vancouver, ISO, and other styles

8

Rosskamp, R. "Safety aspects of oral hypoglycaemic agents." Diabetologia 39, no. 12 (1996): 1668–72. http://dx.doi.org/10.1007/s001250050632.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Batra, Chandar M., Kiran Kumar, and Monica Goyal. "D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring." Indian Journal of Endocrinology and Metabolism 26, Suppl 1 (2022): S1. http://dx.doi.org/10.4103/2230-8210.342324.

Full text

Abstract:

A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euthyroid on treatment. The physical examination was unremarkable. Her liver, renal functions, thyroid, and adrenal functions were normal. At blood sugar of 23 mg/dl, her serum insulin was 24000uU/ml (normal<3uU/ml) and c-peptide was 16.2 ng/ml (normal 0-0.6ng/ml) which were very high. As the serum i

APA, Harvard, Vancouver, ISO, and other styles

10

Mkele, Gail. "Where do sulphonylureas fit in the type 2 diabetes guidelines?" South African Family Practice 56, no. 4 (2014): 2. http://dx.doi.org/10.4102/safp.v56i4.4190.

Full text

Abstract:

Sulphonylureas act by binding to sulphonylurea receptors and stimulating insulin secretion from pancreatic beta cells. This class of oral hypoglycaemic agents is still widely used in the management of type 2 diabetes in patients where lifestyle changes alone are insufficient. Although the older-generation sulphonylureas no longer have a place in therapy, the newer-generation sulphonylureas are a widely recognised choice, either as monotherapy, or in combination with insulin and/or other oral hypoglycaemic agents.

APA, Harvard, Vancouver, ISO, and other styles

11

Jian, Low Qin. "A Fatal Case of Metformin and Gliclazide Poisoning and its Management." Borneo Journal of Medical Sciences (BJMS) 11, no. 3 (2017): 35–40. http://dx.doi.org/10.51200/bjms.v11i3.978.

Full text

Abstract:

Both metformin and gliclazide have been used extensively in the management of type II diabetes mellitus.Â Metformin and gliclazide overdoseÂ can lead to severe hypoglycaemia refractory to intravenous (IV) dextrose rescue therapy. A 21-year-old man complained of vomiting and felt dizzy after four hours of taking 70 tablets of Metformin 500 mg and 40 tablets of Gliclazide 80 mg. He had major depressive disorder and wanted to commit suicide. He was given IV Dextrose 50% 50 cc immediately. Octreotide had been used successfully to reverse the refractory hypoglycaemia caused by gliclazide overdose.

APA, Harvard, Vancouver, ISO, and other styles

12

Marchetti, Piero, and Renzo Navalesi. "Pharmacokinetic-Pharmacodynamic Relationships of Oral Hypoglycaemic Agents." Clinical Pharmacokinetics 16, no. 2 (1989): 100–128. http://dx.doi.org/10.2165/00003088-198916020-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hill, Jill. "Managing insulin resistance with oral hypoglycaemic agents." British Journal of Cardiac Nursing 2, no. 4 (2007): 182–87. http://dx.doi.org/10.12968/bjca.2007.2.4.23454.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hellmuth, E., P. Damm, and L. Molsted-Pedersen. "Oral hypoglycaemic agents in 118 diabetic pregnancies." Diabetic Medicine 17, no. 7 (2000): 507–11. http://dx.doi.org/10.1046/j.1464-5491.2000.00314.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Steel, J. M., and I. W. Campbell. "Oral hypoglycaemic agents in 188 diabetic pregnancies." Diabetic Medicine 18, no. 7 (2001): 604. http://dx.doi.org/10.1046/j.1464-5491.2001.00448-2.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Steel, J. M., and I. W. Campbell. "Oral hypoglycaemic agents in 188 diabetic pregnancies." Diabetic Medicine 18, no. 7 (2001): 604. http://dx.doi.org/10.1046/j.1464-5491.2001.00448.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Plank, Johannes, and Gerlies-Maria Bock. "Hypoglycaemic Agents for Type 2 Diabetes mellitus." Wiener Medizinische Wochenschrift 153, no. 21-22 (2003): 452–58. http://dx.doi.org/10.1007/s10354-003-0034-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Calabuig, C., G. M. Antón-Fos, J. Gálvez, and R. Garcı́a-Doménech. "New hypoglycaemic agents selected by molecular topology." International Journal of Pharmaceutics 278, no. 1 (2004): 111–18. http://dx.doi.org/10.1016/j.ijpharm.2004.03.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Nabarro, John D. N. "Oral Hypoglycaemic Agents: The First Thirty Years." Journal of the Royal College of Physicians of London 26, no. 1 (1992): 50–55. https://doi.org/10.1016/s0035-8819(25)01883-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Heller, Simon R., Milan S. Geybels, Ahmed Iqbal, Lei Liu, Lily Wagner, and Elaine Chow. "A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study." Diabetologia 65, no. 1 (2021): 55–64. http://dx.doi.org/10.1007/s00125-021-05556-7.

Full text

Abstract:

Abstract Aims/hypothesis Hypoglycaemia is a common side effect of insulin and some other antihyperglycaemic agents used to treat diabetes. Severe hypoglycaemia has been associated with adverse cardiovascular events in trials of intensive glycaemic control in type 2 diabetes. The relationship between non-severe hypoglycaemic episodes (NSHEs) and severe hypoglycaemia in type 2 diabetes has been documented. However, an association between more frequent NSHEs and cardiovascular events has not been verified. This post hoc analysis of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation

APA, Harvard, Vancouver, ISO, and other styles

21

Asfandiyarova, Nailya Sayfullaevna. "A review of mortality in type 2 diabetes mellitus." Diabetes mellitus 18, no. 4 (2015): 12–21. http://dx.doi.org/10.14341/dm6846.

Full text

Abstract:

The morbidity and mortality associated with type 2 diabetes have increased over recent years. The causes of death include cardiovascular disease, cancer, infection, kidney disease and diabetic coma. Risk factors for death are a sedentary lifestyle, obesity, smoking, sex, age, duration and severity of diabetes, macro- and microvascular complications and hyper- and hypoglycaemic states. Adequate glycemic control and moderate exercise along with the use of antiplatelet agents (e.g. aspirin), statins, antihypertensives and metformin can reduce mortality. Intensive glucose control was associated wi

APA, Harvard, Vancouver, ISO, and other styles

22

YOGEV, YARIV, and ODED LANGER. "THE USE OF ANTI-HYPERGLYCAEMIC AND HYPOGLYCAEMIC AGENTS IN PREGNANCY." Fetal and Maternal Medicine Review 15, no. 2 (2004): 133–43. http://dx.doi.org/10.1017/s096553950400124x.

Full text

Abstract:

Gestational diabetes (GDM) has an estimated incidence of 3–10%, depending upon geography and ethnic origin; it is considered by many to be a major health concern for the mother and fetus. Dietary modification and pharmacological therapy are the principal means employed to control maternal hyperglycemia. The two main pharmacological options for GDM management are administration of insulin or the use of oral hypoglycaemic and anti-hyperglycaemic drugs. Although controversy continues regarding the need for hypoglycaemic agents in all GDM women, approximately 30–60% do require pharmacological ther

APA, Harvard, Vancouver, ISO, and other styles

23

Patel, A. K., J. Kaur, D. K. Yadav, S. V. Rajendra, and M. Roy. "INFLUENCE OF FLUCONAZOLE ON HYPOGLYCAEMIC ACTIVITY OF ORAL ANTIDIABETIC AGENTS IN HEALTHY RATS." INDIAN DRUGS 54, no. 05 (2017): 50–55. http://dx.doi.org/10.53879/id.54.05.10614.

Full text

Abstract:

The influence of fluconazole pre-treatment on the hypoglycaemic effect of pioglitazone (10 mg/kg, p.o) and rosiglitazone (720 μg/kg, p.o) was studied. This study was conducted on healthy albino rats of either sex, randomly distributed into four different groups. They were pretreated with fluconazole (18 mg/kg and 36 mg/kg, p.o for 7 days) in 2% w/V gum acacia suspension for seven days. On eighth day, rosiglitazone and pioglitazone were administered to respective groups one hour after fluconazole treatment. Blood samples were collected by retro orbital plexus under light ether anesthesia at tim

APA, Harvard, Vancouver, ISO, and other styles

24

Dharini, Ravichandran, Sudeep Jain, Ragini Bhake, Vedavati B. Purandare, and Ambika G. Unnikrishnan. "Postbariatric Hypoglycaemia." Chronicle of Diabetes Research and Practice 4, no. 1 (2025): 49–53. https://doi.org/10.4103/cdrp.cdrp_15_24.

Full text

Abstract:

Post-bariatric hypoglycaemia (PBH) is a metabolic complication of bariatric surgery which is characterized by low glucose levels in patients following bariatric procedures. The development of postbariatric hypoglycaemia can be dangerous and also significantly impact patients’ quality of life and mental health. Timely diagnosis of PBH and prompt treatment in patients suffering from it is crucial. This case report describes the management of postbariatric hypoglycaemia in a 56-year-old female who had undergone sleeve gastrectomy 16 years ago. She presented to our outpatient department with postp

APA, Harvard, Vancouver, ISO, and other styles

25

Holstein, A., A. Plaschke, M. Ptak, et al. "Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents." British Journal of Clinical Pharmacology 60, no. 1 (2005): 103–6. http://dx.doi.org/10.1111/j.1365-2125.2005.02379.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Bennett, Stephen. "Oral hypoglycaemic agents: uses, actions and prescribing rationale." Nurse Prescribing 7, no. 7 (2009): 314–19. http://dx.doi.org/10.12968/npre.2009.7.7.43307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Holt, R. I. G., and K. D. Lambert. "The use of oral hypoglycaemic agents in pregnancy." Diabetic Medicine 31, no. 3 (2014): 282–91. http://dx.doi.org/10.1111/dme.12376.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Yukio, Ozaki, Yatomi Yutaka, and Kume Shoji. "Effects of oral hypoglycaemic agents on platelet functions." Biochemical Pharmacology 44, no. 4 (1992): 687–91. http://dx.doi.org/10.1016/0006-2952(92)90404-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Batra, C. M., Savita Jain1, P. Kiran Kumar2, Monika Goyal3, and Varsha Kachroo4. "Abstract 17: Spontaneous hypoglycaemia due to insulin autoimmune syndrome in five cases, response to steroid therapy and rituximab." Indian Journal of Endocrinology and Metabolism 26, Suppl 1 (2022): S12. http://dx.doi.org/10.4103/2230-8210.342131.

Full text

Abstract:

Insulin autoimmune syndrome, a rare autoimmune syndrome known as Hirata's disease, was first described by Dr. Hirata of Japan in 1970. It presents as spontaneous recurrent hypoglycaemic attacks. The characteristic presence of anti-insulin auto-antibodies (IAA), increased serum insulin and c peptide levels are the hallmark of this syndrome. It is the third most common cause of spontaneous endogenous hypoglycaemia in Japan. It is triggered by either viruses or sulfhydryl group containing drugs in patients with a genetic predisposition. However, in some cases, no triggering factor is found. In 82

APA, Harvard, Vancouver, ISO, and other styles

30

Lindo, Ruby Alexander, Coleen Salmon, and Donovan Mcgrowder. "THE HYPOGLYCAEMIC EFFECT OF OLEANONIC ACID ISOLATED FROM PILEA ELIZABETHAE IN A RAT MODEL." International Journal of Current Pharmaceutical Research 9, no. 6 (2017): 63. http://dx.doi.org/10.22159/ijcpr.2017v9i6.23431.

Full text

Abstract:

Objective: The objective of this study is to isolate and identify the chief hypoglycaemic component of Pilea elizabethaeMethods: The chief hypoglycaemic component of Pilea elizabethaewas isolated and identified. The bio-directed purification of the chief hypoglycaemic agents contained in Pilea elizabethae followed a sequence of steps alternating oral glucose tolerance test (OGTT) bioassay and chromatographic methods. The ethyl acetate crude extract which was most hypoglycaemic in activity was flash chromatographed on silica gel using a gradient hexane-ethyl acetate solvent system of increasing

APA, Harvard, Vancouver, ISO, and other styles

31

Rowe, BethR, John Thorpe, and Anthony Barnett. "Safety of fluconazole in women taking oral hypoglycaemic agents." Lancet 339, no. 8787 (1992): 255–56. http://dx.doi.org/10.1016/0140-6736(92)90072-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Pogorelova, A. S. "A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus." Medical Council, no. 12 (July 29, 2018): 118–26. http://dx.doi.org/10.21518/2079-701x-2018-12-118-126.

Full text

Abstract:

Due to the growing prevalence and progression of type 2 diabetes mellitus (DM), the researchers continue the search for the optimal drug not only to achieve the target level of glycaemic control, but also to reduce body weight and the risk of hypoglycaemic conditions. The new combinations of hypoglycaemic drugs are being developed in order to increase adherence to treatment. The studies showed that the addition of a single injection of a fixed combination of insulin degloudec/liraglutide is effective for glycaemic control and weight loss, generally well tolerated by patients and is preferred i

APA, Harvard, Vancouver, ISO, and other styles

33

Loh, K. C., and M. K. S. Leow. "Current Therapeutic Strategies for Type 2 Diabetes Mellitus." Annals of the Academy of Medicine, Singapore 31, no. 6 (2002): 722–30. https://doi.org/10.47102/annals-acadmedsg.v31n6p722.

Full text

Abstract:

Type 2 diabetes mellitus is now regarded a worldwide epidemic with diabetes-related complications exacting a heavy toll on those with poor metabolic control. Although there is no cure currently, the therapeutic armamentarium has expanded over the last few years to five classes of oral agents – sulfonylureas, biguanides, meglitinides, thiazolidinediones and alpha-glucosidase inhibitors. Sulfonylureas continue to be the mainstay oral hypoglycaemic agents for type 2 diabetics because they are potent insulin secretagogues and cost-effective. Metformin exerts its main effect by reducing hepatic glu

APA, Harvard, Vancouver, ISO, and other styles

34

Di, Yuan Ming, Lu Sun, Chuanjian Lu, et al. "Benefits of herbal formulae containing Poria cocos (Fuling) for type 2 diabetes mellitus: A systematic review and meta-analysis." PLOS ONE 17, no. 12 (2022): e0278536. http://dx.doi.org/10.1371/journal.pone.0278536.

Full text

Abstract:

Background Poria cocos (Schw.) Wolf or Fuling is one of the top 10 most frequently prescribed herbs in China for the treatment of type 2 diabetes mellitus (T2DM). Objective The purpose of this systematic review is to determine the additional benefit of Fuling formulae use in addition to hypoglycaemic agents for T2DM in randomised clinical trials. Methods English (5) and Chinese (4) medical databases were searched from their inception to August 2021. RCTs that included Fuling in herbal formulae for T2DM were included. Risk of bias were assessed using the Cochrane Collaboration’s procedures. Sta

APA, Harvard, Vancouver, ISO, and other styles

35

Ho, Francis LW, Choon-Fong Liew, Elaine C. Cunanan, and Kok-Onn Lee. "Oral Hypoglycaemic Agents for Diabetes in Pregnancy – An Appraisal of the Current Evidence for Oral Anti-diabetic Drug Use in Pregnancy." Annals of the Academy of Medicine, Singapore 36, no. 8 (2007): 672–78. http://dx.doi.org/10.47102/annals-acadmedsg.v36n8p672.

Full text

Abstract:

Introduction: The use of oral hypoglycaemic drugs in pregnancy is not recommended because of reports of foetal anomalies and other adverse outcomes in animal studies and in some human cases. However, recent studies have suggested that some oral hypoglycaemic drugs may be used in pregnancy. This review will examine these studies critically. Methods: Literature review of articles obtained from a PubMed search of peer-reviewed journals on oral hypoglycaemic drug use in pregnancy. Results: In two prospective studies, one of which was a randomised controlled trial, glibenclamide was as effective an

APA, Harvard, Vancouver, ISO, and other styles

36

Tsang, Man-Wo. "The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents." ISRN Endocrinology 2012 (May 7, 2012): 1–9. http://dx.doi.org/10.5402/2012/478120.

Full text

Abstract:

Type 2 Diabetes Mellitus (T2DM) is characterized by chronic hyperglycemia with disturbance in carbohydrate, lipid, and protein metabolism due to insulin resistance and beta cell dysfunction. Epidemiological studies have confirmed a global pandemic of T2DM, which has created an enormous burden on society, with regard to morbidity, mortality, and health care expenditures. Life style modifications are fundamental not only in early stages of disease management but need to be intensified as disease progresses. United Kingdom Prospective Diabetes Study (UKPDS) has demonstrated the progressive nature

APA, Harvard, Vancouver, ISO, and other styles

37

Game, Fran. "Novel Hypoglycaemic Agents: Considerations in Patients with Chronic Kidney Disease." Nephron Clinical Practice 126, no. 1 (2014): 14–18. http://dx.doi.org/10.1159/000357680.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kalashnikova, Marina Fedorovna, Dmitriy Yur'evich Belousov, Yury Ivanovich Suntsov, Maria Alexeevna Kantemirova, and Ivan Ivanovich Dedov. "Pharmacoepidemiological and pharmacoeconomic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow." Diabetes mellitus 18, no. 2 (2015): 32–46. http://dx.doi.org/10.14341/dm2015232-46.

Full text

Abstract:

Pharmacoepidemiological research is the first stage of the clinical and economical evaluation of treatment with pharmaceutical agents. It plays an important role in providing reliable information about treatment regimens for patients with type 2 diabetes mellitus (T2DM). The results of the analysis of the utilisation of hypoglycaemic drugs are country specific and are associated with different epidemiological characteristics of the disease, cost of drugs and financing of the healthcare system. Analytical pharmacoeconomic studies allow the evaluation of the rational use of drugs, characteristic

APA, Harvard, Vancouver, ISO, and other styles

39

Martin, G., and J. Rand. "Current Understanding of Feline Diabetes: Part 2, Treatment." Journal of Feline Medicine and Surgery 2, no. 1 (2000): 3–17. http://dx.doi.org/10.1053/jfms.2000.0057.

Full text

Abstract:

When treating diabetic cats, the primary aim is to control clinical signs without causing clinical hypoglycaemia. Secondary goals are to maximise the chances of attaining diabetic remission and to minimise the risk of complications due to chronic hyperglycaemia. A treatment plan that is convenient for the owner is important for compliance. Underweight or overweight diabetic cats should be fed with the aim of normalising bodyweight. Current evidence suggests that non-obese diabetic cats can be fed ad libitum. The oral hypoglycaemic drug glipizide is well established as a treatment for about a t

APA, Harvard, Vancouver, ISO, and other styles

40

Ben-David, Eyal, Richard Hull, and Debasish Banerjee. "Diabetes mellitus in dialysis and renal transplantation." Therapeutic Advances in Endocrinology and Metabolism 12 (January 2021): 204201882110486. http://dx.doi.org/10.1177/20420188211048663.

Full text

Abstract:

Diabetes mellitus is the commonest cause of end-stage kidney failure worldwide and is a proven and significant risk factor for the development of cardiovascular disease. Renal impairment has a significant impact on the physiology of glucose homeostasis as it reduces tissue sensitivity to insulin and reduces insulin clearance. Renal replacement therapy itself affects glucose control: peritoneal dialysis may induce hyperglycaemia due to glucose-rich dialysate and haemodialysis often causes hypoglycaemia due to the relatively low concentration of glucose in the dialysate. Autonomic neuropathy whi

APA, Harvard, Vancouver, ISO, and other styles

41

Madar, Zecharia, and Aliza H. Stark. "New legume sources as therapeutic agents." British Journal of Nutrition 88, S3 (2002): 287–92. http://dx.doi.org/10.1079/bjn2002719.

Full text

Abstract:

This review evaluates the potential health benefits of three legume sources that rarely appear in Western diets and are often overlooked as functional foods. Fenugreek (Trigonella foenum graecum) and isolated fenugreek fractions have been shown to act as hypoglycaemic and hypocholesterolaemic agents in both animal and human studies. The unique dietary fibre composition and high saponin content in fenugreek appears to be responsible for these therapeutic properties. Faba beans (Vicia faba) have lipid-lowering effects and may also be a good source of antioxidants and chemopreventive factors. Mun

APA, Harvard, Vancouver, ISO, and other styles

42

Nedosugova, Lyudmila Viktorovna, Nina Alexandrovna Petunina, and Karina Oganesovna Galstyan. "Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia." Diabetes mellitus 17, no. 4 (2014): 81–86. http://dx.doi.org/10.14341/dm2014481-86.

Full text

Abstract:

Current treatment strategies for type 2 diabetes mellitus (T2DM) are based on using safe and effective hypoglycaemic agents for preventing diabetic vascular complications and reducing the risks associated with weight gain and hypoglycaemia. These goals may be achieved using new agents with a fundamentally new mechanism of action: inhibitors of dipeptidyl peptidase-4 (DPP-4i). However, the wide distribution of this enzyme in the body is associated with extraglycaemic DPP-4i effects, both positive and negative. Thus, it is important to develop and implement new DPP-4i agents for clinical practic

APA, Harvard, Vancouver, ISO, and other styles

43

Kabade, Durgaprasad M., Anand Koppad, Ameet Khatawkar, Savitri D. Kabade, and Afaq Ahmed. "ORAL HYPOGLYCAEMIC AGENTS IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS." Journal of Evidence Based Medicine and Healthcare 3, no. 45 (2016): 2272–82. http://dx.doi.org/10.18410/jebmh/2016/503.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Gnudi, Luigi, and Janaka Karalliedde. "Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents." Nephrology Dialysis Transplantation 31, no. 7 (2015): 1036–43. http://dx.doi.org/10.1093/ndt/gfv093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Datar, Prasanna A., and Sonali R. Jadhav. "Design and Synthesis of Pyrazole-3-one Derivatives as Hypoglycaemic Agents." International Journal of Medicinal Chemistry 2015 (February 4, 2015): 1–10. http://dx.doi.org/10.1155/2015/670181.

Full text

Abstract:

Pyrazole-3-one compounds were designed on the basis of docking studies of previously reported antidiabetic pyrazole compounds. The amino acid residues found during docking studies were used as guidelines for the modification of aromatic substitutions on pyrazole-3-one structure. Depending on the docking score, the designed compounds were selectively prioritized for synthesis. The synthesized compounds were subjected to in vivo hypoglycemic activity using alloxan induced diabetic rats and metformin as a standard. Compound 4 having sulphonamide derivative was found to be the most potent compound

APA, Harvard, Vancouver, ISO, and other styles

46

Skett, P., and A. H. Hussin. "A direct action of oral hypoglycaemic agents on the rat liver?" European Journal of Pharmacology 183, no. 2 (1990): 287. http://dx.doi.org/10.1016/0014-2999(90)93140-l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Nicholson, Wanda, and Kesha Baptiste-Roberts. "Oral hypoglycaemic agents during pregnancy: The evidence for effectiveness and safety." Best Practice & Research Clinical Obstetrics & Gynaecology 25, no. 1 (2011): 51–63. http://dx.doi.org/10.1016/j.bpobgyn.2010.10.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Pontiroli, Antonio E., Anna Caiderara, and Guido Pozza. "Secondary failure of oral hypoglycaemic agents: Frequency, possible causes, and management." Diabetes / Metabolism Reviews 10, no. 1 (1994): 31–43. http://dx.doi.org/10.1002/dmr.5610100104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Winocour, Peter H., Karen Moore-Haines, Keith Sullivan, Anne Currie, Andrew Solomon, and Dawn Hardy. "HbA1c in a primary care cohort with diabetes and chronic kidney disease: the East and North Hertfordshire Institute of Diabetes and Endocrinology (ENHIDE) Diabetes Renal Telehealth Project." British Journal of Diabetes 20, no. 2 (2020): 130–37. http://dx.doi.org/10.15277/bjd.2020.252.

Full text

Abstract:

Aim: Diabetes mellitus and chronic kidney disease (CKD) commonly co-occur. Control of glycaemia is nuanced, and should be individualised. The Diabetes Renal Telehealth Project identified 2,356 adults with diabetes and CKD, and evaluated determinants and patterns of HbA1c in order to identify under-treatment or potential over-treatment of glycaemia.Method: Comprehensive review of GP diabetes registers by the clinical investigators.Results: The study subjects (52% male, 48% female) were aged 77 years (range 19–103) with median estimated glomerular filtration rate 52 (range 3–171) mL/min and medi

APA, Harvard, Vancouver, ISO, and other styles

50

Goyal, Rajan, Himanshu Jindal, Abhilasha Singh, and Abhishek Kamendu. "Evaluation of Pattern of Use of Prescribed Oral Hypoglycaemic Drugs in Newly Diagnosed Diabetic Nephropathy Patients Visiting a Tertiary Care Hospital of Southern Bihar." Journal of Evidence Based Medicine and Healthcare 7, no. 43 (2020): 2492–96. http://dx.doi.org/10.18410/jebmh/2020/515.

Full text

Abstract:

BACKGROUND Diabetes is the most important risk factor for chronic kidney disease. Because of this, clearance of many oral hypoglycaemic drugs from our body is hampered and time of exposure to these drugs increases. Therefore, patients of diabetes need to be assessed frequently for the development of diabetic nephropathy and the dosage of oral hypoglycaemic drugs should also be modified accordingly. So, the purpose of this study was to evaluate the doses of prescribed OHAs in newly diagnosed diabetic nephropathy patients. METHODS A hospital based observational study was conducted at Narayan Med

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!